This is a staging instance. Full-text downloads are disabled.
 

Publication:
Tumoral heterogeneity in neuroblastoma

dc.contributor.authorGomez, Roshna Lawrence
dc.contributor.authorIbragimova, Shakhzada
dc.contributor.authorRamachandran, Revathy
dc.contributor.authorAli, Fahad R
dc.date.accessioned2023-04-25T08:09:08Z
dc.date.available2023-04-25T08:09:08Z
dc.date.issued2022
dc.description.abstractAbstract: Neuroblastoma is a solid, neuroendocrine tumor with divergent clinical behavior ranging from asymptomatic to fatal. The diverse clinical presentations of neuroblastoma are directly linked to the high intra- and inter-tumoral heterogeneity it presents. This heterogeneity is strongly associated with therapeutic resistance and continuous relapses, often leading to fatal outcomes. The development of successful risk assessment and tailored treatment strategies lies in evaluating the extent of heterogeneity via the accurate genetic and epigenetic profiling of distinct cell subpopulations present in the tumor. Recent studies have focused on understanding the molecular mechanisms that drive tumoral heterogeneity in pursuing better therapeutic and diagnostic approaches. This review describes the cellular, genetic, and epigenetic aspects of neuroblastoma heterogeneity. In addition, we summarize the recent findings on three crucial factors that can lead to heterogeneity in solid tumors: the inherent diversity of the progenitor cells, the presence of cancer stem cells, and the influence of the tumor microenvironment.en_US
dc.identifier.other204-2022.129
dc.identifier.urihttps://repository.mbru.ac.ae/handle/1/1171
dc.language.isoenen_US
dc.subjectNeuroblastomaen_US
dc.subjectHeterogeneityen_US
dc.subjectTumor Originen_US
dc.subjectCancer Stem Cellen_US
dc.subjectTumor Microenvironmenten_US
dc.titleTumoral heterogeneity in neuroblastomaen_US
dc.typeArticleen_US
dspace.entity.typePublication

Files